bioRxiv Science⌕ Search

Biology subjects

Brusel, M.

Publications and source records attributed to Brusel, M..

6 recordsLinked to original sources

Alterations in background ECoG activity and behavioral deficits in a mouse model of CHD2-related developmental delay

Heterozygous loss of function mutations in the CHD2 gene, encoding for chromodomain helicase DNA-binding protein 2, are associated with severe childhood-onset epilepsy, global developmental delay, and autistic features. Here, we characterized the behavioral and epileptic phenotypes of a mouse model harboring a frameshift truncating mutation in the Chd2 gene (Chd2WT/m and Chd2m/m mice). Genetic background dramatically affected the phenotypes. While no phenotypes were observed on the pure C57BL/6J background, crossing these mice onto the 129X1/SvJ genetic background gradually uncovered neurodevelopmental phenotypes. Transcriptomic analysis identified Kcnj11 as a potential genetic modifier. On the 129X1/SvJ background, Chd2m/m mice demonstrated growth retardation, and both Chd2WT/m and Chd2m/m showed motor deficits, including clasping behavior and reduced abilities to balance on a rotating rod. Autistic-like features were also observed, with Chd2m/m showing reduced nest-building abilities and Chd2WT/m demonstrating increased repetitive-like behavior in the marble burying test and altered social behavior. Quantitative analysis of electrocorticographic (ECoG) recordings revealed neuronal changes consisting of a global reduction in the total power of background activity in Chd2WT/m and Chd2m/m mice, as well as increased susceptibility to seizures induced by acute administration of 4-aminopyridine. Overall, this mouse model recapitulates multiple key phenotypes observed in CHD2 patients, providing a valuable platform to study the molecular basis and treatment options for this intractable disease.

neuroscience↗

The SCN8A p.(Gly1625Arg) variant associated with developmental and epileptic encephalopathy causes complex biophysical changes and reduced neuronal firing

BackgroundMutations in the SCN8A gene, encoding the voltage-gated sodium channel NaV1.6, lead to various neurodevelopmental disorders. The SCN8A p.(Gly1625Arg) mutation (NaV1.6G1625R) was identified in a patient diagnosed with developmental epileptic encephalopathy (DEE), presenting with moderate epilepsy and severe developmental delay. MethodsWe performed biophysical and neurophysiological characterizations of NaV1.6G1625R in Neuro-2a cells and cultured hippocampal neurons, followed by computational modeling to determine the impact of its heterozygous expression on cortical neuron function. FindingsVoltage-clamp analyses of NaV1.6G1625R demonstrated a heterogeneous mixture of gain-and loss-of-function properties, including reduced current amplitudes, a marked increase in the time constant of fast voltage-dependent inactivation and a depolarizing shift in the voltage dependence of inactivation. Recordings in transfected cultured neurons showed that these intricate biophysical properties had a minor effect on neuronal excitability when firing relayed on both endogenous and transfected NaV channels. Conversely, there was a marked reduction in the number of action potentials when firing was driven by the transfected mutant NaV1.6 channels. Computational modeling of mature cortical neurons further revealed a mild reduction in neuronal firing when mimicking the patients heterozygous NaV1.6G1625R expression. Structural modeling of NaV1.6G1625R and a double-mutant cycle analysis suggested the possible formation of pathophysiologically-relevant cation-{pi} interaction between R1625 and F1588, affecting the voltage dependence of inactivation. InterpretationOur analyses demonstrate a complex combination of gain and loss-of-function changes resulting in an overall mild reduction in neuronal firing, related to a perturbed interaction network within the voltage sensor domain. FundingISF, DFG, BMBF, The Hartwell Foundation, ICRF, ISCA Research in contextO_ST_ABSEvidence before this studyC_ST_ABSMutations in the SCN8A gene, encoding the voltage-gated sodium channel NaV1.6, result in multiple neurodevelopmental syndromes ranging from benign epilepsy to developmental delay without epilepsy or developmental epileptic encephalopathy (DEE). Recent studies established that most DEE-causing SCN8A mutations result in a gain of function effect. However, several SCN8A mutations that diverge from this pattern were described. Added value of this studyWe performed a multi-tiered study of the SCN8A p.(Gly1625Arg) variant (NaV1.6G1625R), identified in a patient with atypical DEE presentation, featuring moderate epilepsy that is well controlled by the sodium channel blocker Oxcarbazepine, along with profound stagnated developmental delay. This variant is positioned within the S4 segment of domain IV, a critical region for NaV1.6 function, where pathogenic variants were shown to cause either a loss or gain of channel function, but often with mixed biophysical alterations. Our biophysical characterization of NaV1.6G1625R in Neuro-2a cells demonstrated complex gain-and loss-of-function properties, cumulating to reduced firing in cultured hippocampal neurons and computational modeling of mature cortical neurons, demonstrating an overall loss-of-function effect. Implications of all the available evidenceOur results indicate the necessity for combined biophysical and neuronal characterization of individual SCN8A variants, especially those presenting with complex biophysical changes or atypical clinical presentation. Moreover, while sodium channel blockers are the recommended treatment for SCN8A variants associated with gain-of-function, additional considerations may be needed for DEE-causing variants that are associated with mild loss-of-function.

physiology↗

Heat-induced seizures, premature mortality, and hyperactivity in a novel Scn1a nonsense model for Dravet syndrome

Dravet syndrome (Dravet) is a severe congenital developmental genetic epilepsy caused by de novo mutations in the SCN1A gene. Nonsense mutations are found in ~20% of the patients, and the R613X mutation was identified in multiple patients. Here we characterized the epileptic and non-epileptic comorbidities of a novel preclinical Dravet mouse model harboring this nonsense Scn1a mutation. Heterozygous Scn1a R613X mutation on a mixed C57BL/6J:129S1/SvImJ background exhibited spontaneous seizures, susceptibility to heat-induced seizures, and premature mortality, recapitulating the core epileptic phenotypes of Dravet. In addition, these mice, available as an open-access model, demonstrated increased locomotor activity in the open-field test, mimicking some non-epileptic Dravet-associated comorbidities. Conversely, Scn1aWT/R613X mice on the pure 129S1/SvImJ background had a normal life span and were easy to breed. Homozygous Scn1aR613X/R613X mice died before P16. Our molecular analyses of hippocampal and cortical expression demonstrated that the premature stop codon induced by the R613X mutation reduced Scn1a mRNA and Nav1.1 protein levels to ~50% in heterozygous Scn1aWT/R613X mice, with marginal expression in homozygous Scn1aR613X/R613X mice. Together, we introduce a novel Dravet model carrying the R613X Scn1a nonsense mutation that can. be used to study the molecular and neuronal basis of Dravet, as well as the development of new therapies associated with SCN1A nonsense mutations in Dravet.

neuroscience↗

Acute effect of antiseizure drugs on background oscillations in Scn1aA1783V Dravet syndrome mouse model

ObjectiveDravet syndrome (Dravet) is a rare and severe form of developmental epileptic encephalopathy. First-line treatment for DS patients includes valproic acid (VA) or clobazam with or without stiripentol (CLB+STP), while sodium channel blockers like carbamazepine (CBZ) or lamotrigine (LTG) are contraindicated. As patients are rarely seizure-free, drug therapy focuses on reducing the seizure burden, as reported by caregivers. In addition to their effect on epileptic phenotypes, antiseizure medications (ASMs) were shown to modify the properties of background neuronal activity. Nevertheless, little is known about these background properties alternations in Dravet. MethodsUtilizing Dravet mice (DS, Scn1aA1783V/WT), we tested the acute effect of several ASMs on background electrocorticography (ECoG) activity and frequency of interictal spikes. ResultsCompared to wild-type mice, background ECoG activity in DS had lower power and reduced phase coherence, which was not corrected by any of the tested ASMs. However, acute administration of Dravet-recommended drugs, including VA or a combination of CLB+STP, caused, in most mice, a reduction of frequency of interictal spikes, alongside an increase in the relative contribution of the beta frequency band. Conversely, CBZ and LTG increased the frequency of interictal spikes with no effect on background spectral properties. Moreover, we uncovered a correlation between the reduction in interictal spike frequency, the drug-induced effect on the power of background activity, and a spectral shift toward higher frequency bands. SignificanceThese data provide a comprehensive analysis of the effect of selected ASMs on the properties of background neuronal oscillations and highlight a possible correlation between their effect on epilepsy and background activity. Thus, examining these properties, following an acute administration, may be used as an additional tool for rapid evaluation of the therapeutic potential of ASMs. Key PointsO_LIReduced background power and phase coherence in Dravet mice C_LIO_LIDS-recommended medicines (VA, CLB+STP) increase the relative beta power C_LIO_LIDS-contraindicated drugs (CBZ, LTG) do not cause spectral changes C_LIO_LICorrelation between reduction in background power and interictal spike frequency C_LIO_LICorrelation between theta to beta bands ratio and interictal spike frequency C_LI

neuroscience↗

Exogenous Nav1.1 activity in excitatory and inhibitory neurons reverts Dravet syndrome comorbidities when delivered post-symptom onset in mice with Dravet

Dravet syndrome (DS), an intractable childhood epileptic encephalopathy with a high fatality rate, is caused by loss-of-function mutations in one allele of SCN1A, which encodes NaV1.1. In contrast to other epilepsies, pharmaceutical treatment for DS is limited. Here, we demonstrate that viral vector-mediated delivery of a codon-modified SCN1A cDNA improves DS comorbidities in juvenile and adolescent DS mice (Scn1aA1783V/WT). Notably, bilateral vector injections into the hippocampus or thalamus of DS mice improved the survival of the mice, reduced the occurrence of epileptic spikes, provided protection from thermally-induced seizures, and corrected background electrocorticography activity. Together, our results provide a proof-of-concept for the potential of SCN1A delivery as a therapeutic approach for infants and adolescents with DS-associated comorbidities.

neuroscience↗

Early hippocampal hyperexcitability followed by disinhibition in a mouse model of Dravet syndrome

Dravet syndrome (Dravet) epilepsy begins with febrile seizures followed by worsening to refractory seizures, with some improvement and stabilization toward adolescence. The neuronal basis of Dravet is debatable, with evidence favoring reduced inhibition or enhanced excitation. Focusing on the firing properties of hippocampal CA1 pyramidal neurons and oriens-lacunosum moleculare (O-LM) interneurons, we provide a comprehensive analysis of the activity of both cell types through the febrile, worsening and stabilization stages. Our data indicate a temporary increase in the excitability of CA1 pyramidal neurons during the febrile stage, which is fully reversed by the onset of spontaneous seizures. In contrast, reduced function of O-LM interneurons persisted from the febrile through the stabilization stages, with the greatest impairment of excitability occurring during the worsening stage. Thus, both excitatory and inhibitory neurons contribute to Dravet, indicating complex and reciprocal pathophysiological neuronal changes during the different stages of the disease.\n\nGraphical abstract\n\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=90 SRC=\"FIGDIR/small/790170v2_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (15K):\norg.highwire.dtl.DTLVardef@220862org.highwire.dtl.DTLVardef@54840eorg.highwire.dtl.DTLVardef@a9d006org.highwire.dtl.DTLVardef@9854ec_HPS_FORMAT_FIGEXP M_FIG C_FIG

neuroscience↗